261 related articles for article (PubMed ID: 24004669)
1. PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma.
Boi M; Rinaldi A; Kwee I; Bonetti P; Todaro M; Tabbò F; Piva R; Rancoita PM; Matolcsy A; Timar B; Tousseyn T; Rodríguez-Pinilla SM; Piris MA; Beà S; Campo E; Bhagat G; Swerdlow SH; Rosenwald A; Ponzoni M; Young KH; Piccaluga PP; Dummer R; Pileri S; Zucca E; Inghirami G; Bertoni F
Blood; 2013 Oct; 122(15):2683-93. PubMed ID: 24004669
[TBL] [Abstract][Full Text] [Related]
2. A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.
Abate F; Todaro M; van der Krogt JA; Boi M; Landra I; Machiorlatti R; Tabbò F; Messana K; Abele C; Barreca A; Novero D; Gaudiano M; Aliberti S; Di Giacomo F; Tousseyn T; Lasorsa E; Crescenzo R; Bessone L; Ficarra E; Acquaviva A; Rinaldi A; Ponzoni M; Longo DL; Aime S; Cheng M; Ruggeri B; Piccaluga PP; Pileri S; Tiacci E; Falini B; Pera-Gresely B; Cerchietti L; Iqbal J; Chan WC; Shultz LD; Kwee I; Piva R; Wlodarska I; Rabadan R; Bertoni F; Inghirami G;
Leukemia; 2015 Jun; 29(6):1390-401. PubMed ID: 25533804
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.
Merkel O; Hamacher F; Griessl R; Grabner L; Schiefer AI; Prutsch N; Baer C; Egger G; Schlederer M; Krenn PW; Hartmann TN; Simonitsch-Klupp I; Plass C; Staber PB; Moriggl R; Turner SD; Greil R; Kenner L
J Pathol; 2015 Aug; 236(4):445-56. PubMed ID: 25820993
[TBL] [Abstract][Full Text] [Related]
4. EMMPRIN (CD147) is induced by C/EBPβ and is differentially expressed in ALK+ and ALK- anaplastic large-cell lymphoma.
Schmidt J; Bonzheim I; Steinhilber J; Montes-Mojarro IA; Ortiz-Hidalgo C; Klapper W; Fend F; Quintanilla-Martínez L
Lab Invest; 2017 Sep; 97(9):1095-1102. PubMed ID: 28581487
[TBL] [Abstract][Full Text] [Related]
5. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
Werner MT; Zhao C; Zhang Q; Wasik MA
Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma.
Eckerle S; Brune V; Döring C; Tiacci E; Bohle V; Sundström C; Kodet R; Paulli M; Falini B; Klapper W; Chaubert AB; Willenbrock K; Metzler D; Bräuninger A; Küppers R; Hansmann ML
Leukemia; 2009 Nov; 23(11):2129-38. PubMed ID: 19657361
[TBL] [Abstract][Full Text] [Related]
7. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations.
Zettl A; Rüdiger T; Konrad MA; Chott A; Simonitsch-Klupp I; Sonnen R; Müller-Hermelink HK; Ott G
Am J Pathol; 2004 May; 164(5):1837-48. PubMed ID: 15111330
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma.
Liu C; Iqbal J; Teruya-Feldstein J; Shen Y; Dabrowska MJ; Dybkaer K; Lim MS; Piva R; Barreca A; Pellegrino E; Spaccarotella E; Lachel CM; Kucuk C; Jiang CS; Hu X; Bhagavathi S; Greiner TC; Weisenburger DD; Aoun P; Perkins SL; McKeithan TW; Inghirami G; Chan WC
Blood; 2013 Sep; 122(12):2083-92. PubMed ID: 23801630
[TBL] [Abstract][Full Text] [Related]
9. Identification of putative pathogenic microRNA and its downstream targets in anaplastic lymphoma kinase-negative anaplastic large cell lymphoma.
Mehrotra M; Medeiros LJ; Luthra R; Sargent RL; Yao H; Barkoh BA; Singh R; Patel KP
Hum Pathol; 2014 Oct; 45(10):1995-2005. PubMed ID: 25128227
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.
Boi M; Todaro M; Vurchio V; Yang SN; Moon J; Kwee I; Rinaldi A; Pan H; Crescenzo R; Cheng M; Cerchietti L; Elemento O; Riveiro ME; Cvitkovic E; Bertoni F; Inghirami G;
Oncotarget; 2016 Nov; 7(48):79637-79653. PubMed ID: 27793034
[TBL] [Abstract][Full Text] [Related]
11. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.
Merkel O; Hamacher F; Laimer D; Sifft E; Trajanoski Z; Scheideler M; Egger G; Hassler MR; Thallinger C; Schmatz A; Turner SD; Greil R; Kenner L
Proc Natl Acad Sci U S A; 2010 Sep; 107(37):16228-33. PubMed ID: 20805506
[TBL] [Abstract][Full Text] [Related]
12. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
Drexler HG; Gignac SM; von Wasielewski R; Werner M; Dirks WG
Leukemia; 2000 Sep; 14(9):1533-59. PubMed ID: 10994999
[TBL] [Abstract][Full Text] [Related]
13. Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas.
Boi M; Zucca E; Inghirami G; Bertoni F
Br J Haematol; 2015 Mar; 168(6):771-83. PubMed ID: 25559471
[TBL] [Abstract][Full Text] [Related]
14. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
Eyre TA; Khan D; Hall GW; Collins GP
Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
[TBL] [Abstract][Full Text] [Related]
15. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes.
Lamant L; de Reyniès A; Duplantier MM; Rickman DS; Sabourdy F; Giuriato S; Brugières L; Gaulard P; Espinos E; Delsol G
Blood; 2007 Mar; 109(5):2156-64. PubMed ID: 17077326
[TBL] [Abstract][Full Text] [Related]
16. Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts.
Scarfò I; Pellegrino E; Mereu E; Kwee I; Agnelli L; Bergaggio E; Garaffo G; Vitale N; Caputo M; Machiorlatti R; Circosta P; Abate F; Barreca A; Novero D; Mathew S; Rinaldi A; Tiacci E; Serra S; Deaglio S; Neri A; Falini B; Rabadan R; Bertoni F; Inghirami G; Piva R;
Blood; 2016 Jan; 127(2):221-32. PubMed ID: 26463425
[TBL] [Abstract][Full Text] [Related]
17. p53 and β-Catenin Expression Predict Poorer Prognosis in Patients With Anaplastic Large-Cell Lymphoma.
Richardson AI; Yin CC; Cui W; Li N; Medeiros LJ; Li L; Zhang D
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e385-e392. PubMed ID: 31078446
[TBL] [Abstract][Full Text] [Related]
18. PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas.
Boi M; Zucca E; Inghirami G; Bertoni F
Leuk Lymphoma; 2015 May; 56(5):1223-8. PubMed ID: 25115512
[TBL] [Abstract][Full Text] [Related]
19. Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma.
Weilemann A; Grau M; Erdmann T; Merkel O; Sobhiafshar U; Anagnostopoulos I; Hummel M; Siegert A; Hayford C; Madle H; Wollert-Wulf B; Fichtner I; Dörken B; Dirnhofer S; Mathas S; Janz M; Emre NC; Rosenwald A; Ott G; Lenz P; Tzankov A; Lenz G
Blood; 2015 Jan; 125(1):124-32. PubMed ID: 25359993
[TBL] [Abstract][Full Text] [Related]
20. ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.
Huang L; Zhang F; Zeng J; Guo H; Liu S; Wei X; Chen F; Jiang X; Liang Z; Liu Y; Li W
Ann Hematol; 2018 Jan; 97(1):149-159. PubMed ID: 29150811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]